These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 9253800)
1. New families with von Willebrand disease type 2M (Vicenza). Zieger B; Budde U; Jessat U; Zimmermann R; Simon M; Kätzel R; Sutor AH Thromb Res; 1997 Jul; 87(1):57-64. PubMed ID: 9253800 [TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A; Berneman Z; Schroyens W; Michiels JJ Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359 [TBL] [Abstract][Full Text] [Related]
3. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Casonato A; Pontara E; Sartorello F; Cattini MG; Sartori MT; Padrini R; Girolami A Blood; 2002 Jan; 99(1):180-4. PubMed ID: 11756169 [TBL] [Abstract][Full Text] [Related]
6. Molecular genetics of type 2 von Willebrand disease. Fressinaud E; Mazurier C; Meyer D Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298 [TBL] [Abstract][Full Text] [Related]
7. In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease 'Vicenza' is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma. d'Alessio PA; Castaman G; Rodeghiero F; de Boer HC; Federici AB; Mannucci PM; de Groot PG; Sixma JJ; Zwaginga JJ Thromb Res; 1992 Jan; 65(2):221-8. PubMed ID: 1579897 [TBL] [Abstract][Full Text] [Related]
8. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235 [TBL] [Abstract][Full Text] [Related]
9. The genetic defect of type I von Willebrand disease "Vicenza" is linked to the von Willebrand factor gene. Randi AM; Sacchi E; Castaman GC; Rodeghiero F; Mannucci PM Thromb Haemost; 1993 Feb; 69(2):173-6. PubMed ID: 8456430 [TBL] [Abstract][Full Text] [Related]
10. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect. Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565 [TBL] [Abstract][Full Text] [Related]
11. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene. Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361 [TBL] [Abstract][Full Text] [Related]
12. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1. Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353 [TBL] [Abstract][Full Text] [Related]
14. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay. Riddell AF; Jenkins PV; Nitu-Whalley IC; McCraw AH; Lee CA; Brown SA Br J Haematol; 2002 Jan; 116(1):187-92. PubMed ID: 11841416 [TBL] [Abstract][Full Text] [Related]
15. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Cattaneo M; Federici AB; Lecchi A; Agati B; Lombardi R; Stabile F; Bucciarelli P Thromb Haemost; 1999 Jul; 82(1):35-9. PubMed ID: 10456451 [TBL] [Abstract][Full Text] [Related]
17. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management. Michiels JJ; van Vliet HH Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362 [TBL] [Abstract][Full Text] [Related]
18. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD. Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681 [TBL] [Abstract][Full Text] [Related]
19. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Mannucci PM; Lombardi R; Bader R; Vianello L; Federici AB; Solinas S; Mazzucconi MG; Mariani G Blood; 1985 Oct; 66(4):796-802. PubMed ID: 3876122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]